Monogenic diabetes: What it teaches us on the common forms of type 1 and type 2 diabetes

Endocrine Reviews

Volumn 37, Issue 3, 2016, Pages 190-222

  Yang, Yisheng ^a   Chan, Lawrence ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MEMBRANE PROTEIN; MYOD1 PROTEIN; NEUROGENIC DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOLUTE CARRIER FAMILY 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLIS3; TRANSCRIPTION FACTOR HNF1A; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG;

ABCC8 GENE; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLELE; B LYMPHOCYTE DIFFERENTIATION; BLOOD GLUCOSE MONITORING; CELL FUNCTION; CELL METABOLISM; EMBRYO DEVELOPMENT; ENDOPLASMIC RETICULUM STRESS; FANCONI RENOTUBULAR SYNDROME; GAIN OF FUNCTION MUTATION; GENE; GENE DELETION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GLUCONEOGENESIS; HAPLOTYPE; HOMEOBOX; HUMAN; HYPERINSULINEMIA; HYPERPROINSULINEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LINKAGE ANALYSIS; LOSS OF FUNCTION MUTATION; META ANALYSIS (TOPIC); MISSENSE MUTATION; MITOCHONDRIAL PERMEABILITY; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TARGET ORGAN; TRANSLATION INITIATION; WOLFRAM SYNDROME; DIABETES MELLITUS; GENETICS;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 84973922991     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2015-1116     Document Type: Review

References (318)

1. Steck AK, Winter WE. Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes. 2011;18(4): 252-258.
2. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosisandtreatment. Curr Diab Rep. 2011;11(6): 519-532.
3. Edghill EL, Dix RJ, Flanagan SE, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55(6): 1895-1898.
4. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014;46(8): 812-814.
5. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34(8): 1878-1884.
6. Gardner DS, Tai ES. Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes. 2012; 5: 101-108.
7. Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32(4): 457-467.
8. Grarup N, Sandholt CH, Hansen T, Pedersen O. Genetic susceptibility to type 2 diabetes and obesity: from genomewide association studies to rare variants and beyond. Diabetologia. 2014;57(8): 1528-1541.
9. Hara K, Shojima N, Hosoe J, Kadowaki T. Genetic architecture of type 2 diabetes. Biochem Biophys Res Commun. 2014;452(2): 213-220.
10. Bonnefond A, Froguel P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metab. 2015;21(3): 357-368.
11. Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6(1): 87-123.
12. Basile KJ, Guy VC, Schwartz S, Grant SF. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep. 2014;14(11): 550.
13. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes. 2010;59(7): 1561-1571.
14. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014; 46(3): 234-244.
15. Fortune MD, Guo H, Burren O, et al. Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. Nat Genet. 2015;47(7): 839-846.
16. McTaggart JS, Clark RH, Ashcroft FM. The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol. 2010; 588: 3201-3209.
17. Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Ann Pediatr Endocrinol Metab. 2014;19(2): 57-68.
18. Shyng SL, Ferrigni T, Shepard JB, et al. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes. 1998;47(7): 1145-1151.
19. Cartier EA, Conti LR, Vandenberg CA, Shyng SL. Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc Natl Acad Sci USA. 2001;98(5): 2882-2887.
20. Taschenberger G, Mougey A, Shen S, Lester LB, LaFranchi S, Shyng SL. Identification of a familial hyperinsulinismcausing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. J Biol Chem. 2002;277(19): 17139-17146.
21. Kapoor RR, Flanagan SE, James CT, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia. 2011;54(10): 2575-2583.
22. Pinney SE, MacMullen C, Becker S, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118(8): 2877-2886.
23. Huopio H, Reimann F, Ashfield R, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 2000;106(7): 897-906.
24. Gussinyer M, Clemente M, Cebrián R, Yeste D, Albisu M, Carrascosa A. Glucose intolerance and diabetes are observed in the long-term follow-up of nonpancreatectomized patients with persistent hyperinsulinemic hypoglycemia of infancy due to mutations in the ABCC8 gene. Diabetes Care. 2008;31(6): 1257-1259.
25. Abdulhadi-Atwan M, Bushman J, Tornovsky-Babaey S, et al. Novel denovomutation in sulfonylurea receptor1presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence. Diabetes. 2008;57(7): 1935-1940.
26. Vieira TC, Bergamin CS, Gurgel LC, Moisés RS. Hyperinsulinemic hypoglycemia evolving to gestational diabetes and diabetes mellitus in a family carrying the inactivating ABCC8 E1506K mutation. Pediatr Diabetes. 2010;11(7): 505-508.
27. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet. 2003;361(9354): 301-307.
28. Arnoux JB, Verkarre V, Saint-Martin C, et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011; 6: 63.
29. Hsu WH, Xiang HD, Rajan AS, Kunze DL, Boyd AE 3rd. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the β cell. J Biol Chem. 1991;266(2): 837-843.
30. Schmidt A, Hescheler J, Offermanns S, et al. Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991;266(27): 18025-18033.
31. de Weille JR, Schmid-Antomarchi H, Fosset M, Lazdunski M. Regulation of ATP-sensitive K+ channels in insulinoma cells: activation by somatostatin and protein kinase C and the role of cAMP. Proc Natl Acad Sci USA. 1989;86(8): 2971-2975.
32. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassiumchannel subunit Kir6. 2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18): 1838-1849.
33. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355(5): 456-466.
34. Proks P, Arnold AL, Bruining J, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Molec Genet. 2006;15(11): 1793-1800.
35. Edghill EL, Flanagan SE, Patch AM, et al. Insulin mutation screening in 1, 044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes. 2008;57(4): 1034-1042.
36. Flanagan SE, Clauin S, Bellanné-Chantelot C, et al. Update of mutations in the genes encoding the pancreatic β -cell K(ATP) channel subunits Kir6. 2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30(2): 170-180.
37. Craig TJ, Shimomura K, Holl RW, Flanagan SE, Ellard S, Ashcroft FM. An in-frame deletion in Kir6. 2 (KCNJ11) causing neonatal diabetes reveals a site of interaction between Kir6. 2 and SUR1. J Clin Endocrinol Metab. 2009;94(7): 2551-2557.
38. Edghill EL, Flanagan SE, Ellard S. Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord. 2010;11(3): 193-198.
39. Bonnefond A, Philippe J, Durand E, et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One. 2012;7(6): e37423.
40. Bowman P, Flanagan SE, Edghill EL, et al. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia. 2012;55(1): 123-127.
41. Männikkö R, Flanagan SE, Sim X, et al. Mutations of the same conserved glutamate residue in NBD2 of the sulfonylurea receptor 1 subunit of the KATP channel can result in either hyperinsulinism or neonatal diabetes. Diabetes. 2011;60(6): 1813-1822.
42. Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet β cell inwardly rectifying K+ channel gene (KIR6. 2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia. 1998;41(12): 1511-1515.
43. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic β -cell KATP channel subunits Kir6. 2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2): 568-572.
44. Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, Permutt MA. E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6. 2) contributes as much to the risk of type II diabetes in Caucasians as the PPAR γ Pro12Ala variant. Diabetologia. 2003;46(1): 136-137.
45. Nielsen EM, Hansen L, Carstensen B, et al. The E23K variant of Kir6. 2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes. 2003;52(2): 573-577.
46. Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5): 1360-1368.
47. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetesassociated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007;56(2): 531-536.
48. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic β -cells. Diabetes. 2000;49(5): 735-740.
49. Lablanche S, Cottet-Rousselle C, Lamarche F, et al. Protection of pancreatic INS-1 β -cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin. Cell Death Dis. 2011; 2: e134.
50. Laukkanen O, Pihlajamäki J, Lindström J, et al. Polymorphisms of the SUR1 (ABCC8) and Kir6. 2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab. 2004;89(12): 6286-6290.
51. Lyssenko V, Almgren P, Anevski D, et al. Genetic prediction of future type 2 diabetes. PLoSMed. 2005;2(12): e345.
52. Baier LJ, Muller YL, Remedi MS, et al. ABCC8 R1420H loss-of-function variant in a Southwest American Indian community: association with increased birth weight and doubled risk of type 2 diabetes. Diabetes. 2015;64(12): 4322-4332.
53. Gloyn AL, Hashim Y, Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of β -cell ATPsensitive K-channel genes SUR1 and Kir6. 2 with type 2 diabetes mellitus (UKPDS 53). Diabet Med. 2001;18(3): 206-212.
54. Sesti G, Laratta E, Cardellini M, et al. The E23K variant of KCNJ11 encoding the pancreatic β -cell adenosine 5'- triphosphate-sensitive potassium channel subunit Kir6. 2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(6): 2334-2339.
55. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6. 2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA. 2004;101(50): 17539-17544.
56. Proks P, Shimomura K, Craig TJ, Girard CA, Ashcroft FM. Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DENDsyndrome. Hum Molec Genet. 2007;16(16): 2011-2019.
57. Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M. The common single nucleotide polymorphism E23Kin K(IR)6. 2 sensitizes pancreaticβ -cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. Diabetes. 2002; 51(suppl 3): S363-S367.
58. Riedel MJ, Boora P, Steckley D, de Vries G, Light PE. Kir6. 2 polymorphisms sensitize β -cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes? Diabetes. 2003;52(10): 2630-2635.
59. Rosengren AH, Braun M, Mahdi T, et al. Reduced insulin exocytosis in human pancreatic β -cells with gene variants linked to type 2 diabetes. Diabetes. 2012;61(7): 1726-1733.
60. Fatehi M, Raja M, Carter C, Soliman D, Holt A, Light PE. The ATP-sensitive K(+) channel ABCC8 S1369A type 2 diabetes risk variant increases MgATPase activity. Diabetes. 2012;61(1): 241-249.
61. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. NEngl JMed. 2006;355(5): 467-477.
62. Thurber BW, Carmody D, Tadie EC, et al. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia. 2015;58(7): 1430-1435.
63. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylureainduced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41(5): 387-390.
64. Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23(3): 245-249.
65. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98(1): 119-124.
66. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturityonset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11): 1512-1526.
67. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274(1): 305-315.
68. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic β cell glucokinase in maintaining glucose homeostasis. Cell. 1995;83(1): 69-78.
69. Byrne MM, Sturis J, Clément K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994;93(3): 1120-1130.
70. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3): 279-286.
71. Rudland VL, Hinchcliffe M, Pinner J, et al. Identifying glucokinase monogenic diabetes in a multiethnic gestational diabetes mellitus cohort: new pregnancy screening criteria and utility of HbA1c. Diabetes Care. 2016;39(1): 50-52.
72. Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0. 1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy cohort. Diabetes Care. 2014;37(5): 1230-1236.
73. Stride A, Shields B, Gill-Carey O, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57(1): 54-56.
74. Tornovsky-Babeay S, Dadon D, Ziv O, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA doublestrand breaks and p53 activity in β cells. Cell Metab. 2014;19(1): 109-121.
75. Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59(12): 3229-3239.
76. Qi Q, Wu Y, Li H, et al. Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia. 2009;52(5): 834-843.
77. Tam CH, Ma RC, So WY, et al. Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents. Diabetes. 2009;58(3): 765-769.
78. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2): 105-116.
79. Muller YL, Piaggi P, Hoffman D, et al. Commongenetic variation in the glucokinase gene (GCK) is associated with type 2 diabetes and rates of carbohydrate oxidation and energy expenditure. Diabetologia. 2014;57(7): 1382-1390.
80. Ingelsson E, Langenberg C, Hivert MF, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59(5): 1266-1275.
81. Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA. Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes. 1997;46(2): 179-186.
82. de la Iglesia N, Veiga-da-Cunha M, Van Schaftingen E, Guinovart JJ, Ferrer JC. Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase. FEBS Lett. 1999;456(2): 332-338.
83. Guillam MT, Hümmler E, Schaerer E, et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet. 1997;17(3): 327-330.
84. Sansbury FH, Flanagan SE, Houghton JA, et al. SLC2A2 mutations can cause neonatal diabetes, suggesting GLUT2 may have a role in human insulin secretion. Diabetologia. 2012;55(9): 2381-2385.
85. De Vos A, Heimberg H, Quartier E, et al. Human and rat β cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest. 1995;96(5): 2489-2495.
86. Santer R, Schneppenheim R, Dombrowski A, Götze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17(3): 324-326.
87. Abbasi F, Azizi F, Javaheri M, Mosallanejad A, Ebrahim-Habibi A, Ghafouri-Fard S. Segregation of a novel homozygous6nucleotide deletion in GLUT2 gene in a Fanconi-Bickel syndrome family. Gene. 2015;557(1): 103-105.
88. Mihout F, Devuyst O, Bensman A, et al. Acute metabolic acidosis in a GLUT2-deficient patient with Fanconi-Bickel syndrome: new pathophysiology insights. Nephrol Dial Transplant. 2014; 29(suppl 4): iv113-iv116.
89. Mannstadt M, Magen D, Segawa H, et al. Fanconi-Bickel syndrome and autosomal recessive proximal tubulopathy with hypercalciuria (ARPTH) are allelic variants caused by GLUT2mutations. J Clin Endocrinol Metab. 2012;97(10): E1978-E1986.
90. Al-Haggar M, Sakamoto O, Shaltout A, Al-Hawari A, Wahba Y, Abdel-Hadi D. Mutation analysis of the GLUT2 gene in three unrelated Egyptian families with Fanconi-Bickel syndrome: revisited gene atlas for renumbering. Clin Exp Nephrol. 2012;16(4): 604-610.
91. Grünert SC, Schwab KO, Pohl M, Sass JO, Santer R. Fanconi-Bickel syndrome: GLUT2 mutations associated with a mild phenotype. Mol Genet Metab. 2012;105(3): 433-437.
92. Janssen RC, Bogardus C, Takeda J, Knowler WC, Thompson DB. Linkage analysis of acute insulin secretion with GLUT2 and glucokinase in Pima Indians and the identification of a missense mutation in GLUT2. Diabetes. 1994;43(4): 558-563.
93. Alcolado JC, Baroni MG, Li SR. Association between a restriction fragment length polymorphism at the liver/islet cell (Glu T 2) glucose transporter and familial type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia. 1991;34(10): 734-736.
94. Barroso I, Luan J, Middelberg RP, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in β -cell function as well as insulin action. PLoS Biol. 2003;1(1): E20.
95. Matsutani A, Koranyi L, Cox N, Permutt MA. Polymorphisms of GLUT2 and GLUT4 genes. Use in evaluation of genetic susceptibility to NIDDMin blacks. Diabetes. 1990;39(12): 1534-1542.
96. Patel P, Bell GI, Cook JT, Turner RC, Wainscoat JS. Multiple restriction fragment length polymorphisms at the GLUT2 locus: GLUT2 haplotypes for genetic analysis of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34(11): 817-821.
97. Tanizawa Y, Riggs AC, Chiu KC, et al. Variability of the pancreatic islet β cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. Diabetologia. 1994;37(4): 420-427.
98. Matsubara A, Tanizawa Y, Matsutani A, Kaneko T, Kaku K. Sequence variations of the pancreatic islet/liver glucose transporter (GLUT2) gene in Japanese subjects with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1995;80(11): 3131-3135.
99. Laukkanen O, Lindström J, Eriksson J, et al. Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2005;54(7): 2256-2260.
100. Kilpeläinen TO, Lakka TA, Laaksonen DE, et al. Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes. Physiol Genomics. 2007;31(2): 264-272.
101. Michau A, Guillemain G, Grosfeld A, et al. Mutations in SLC2A2 gene reveal hGLUT2 function in pancreatic β cell development. J Biol Chem. 2013;288(43): 31080-31092.
102. Burgdorf KS, Grarup N, Justesen JM, et al. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55, 521 Europeans. PLoS One. 2011;6(1): e15813.
103. Willer CJ, Bonnycastle LL, Conneely KN, et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes. 2007;56(1): 256-264.
104. Eny KM, Wolever TM, Fontaine-Bisson B, El-Sohemy A. Genetic variant in the glucose transporter type 2 is associated with higher intakes of sugars in two distinct populations. Physiol Genomics. 2008;33(3): 355-360.
105. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes. 2000;49(10): 1643-1648.
106. Roncero I, Alvarez E, Chowen JA, et al. Expression of glucose transporter isoform GLUT-2 and glucokinase genes in human brain. J Neurochem. 2004;88(5): 1203-1210.
107. Li B, Xi X, Roane DS, Ryan DH, Martin RJ. Distribution of glucokinase, glucose transporter GLUT2, sulfonylurea receptor-1, glucagon-like peptide-1 receptor and neuropeptide Ymessenger RNAs in rat brain by quantitative real time RT-PCR. Brain Res Mol Brain Res. 2003; 113: 139-142.
108. Pontoglio M, Barra J, Hadchouel M, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 1996;84(4): 575-585.
109. Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1α -deficient mice. J Clin Invest. 1998;101(10): 2215-2222.
110. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 1996;10(2): 267-282.
111. Chen WS, Manova K, Weinstein DC, et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 1994;8(20): 2466-2477.
112. Boj SF, Parrizas M, Maestro MA, Ferrer J. A transcription factor regulatory circuit in differentiated pancreatic cells. Proc Natl Acad Sci USA. 2001;98(25): 14481-14486.
113. Stride A, Ellard S, Clark P, et al. β -Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1α mutation carriers. Diabetes Care. 2005;28(7): 1751-1756.
114. Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012;97(10): E2026-E2030.
115. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12): 2504-2508.
116. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 α (HNF1A) and 4 α (HNF4A) in maturity-onset diabetes of the young. Hum Mutat. 2006;27(9): 854-869.
117. Pontoglio M, Prié D, Cheret C, et al. HNF1 α controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1(4): 359-365.
118. Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. The hepatic nuclear factor-1α G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab. 1999;84(3): 1077-1082.
119. SIGMA Type 2 Diabetes Consortium, Estrada K, Aukrust I, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA. 2014;311(22): 2305-2314.
120. Andersen MK, Sterner M, Forsén T, et al. Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia. 2014;57(9): 1859-1868.
121. Silander K, Mohlke KL, Scott LJ, et al. Genetic variation near the hepatocyte nuclear factor-4 α gene predicts susceptibility to type 2 diabetes. Diabetes. 2004;53(4): 1141-1149.
122. Love-Gregory LD, Wasson J, Ma J, et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 α gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes. 2004;53(4): 1134-1140.
123. Weedon MN, Owen KR, Shields B, et al. Commonvariants of the hepatocyte nuclear factor-4α P2 promoter are associated with type 2 diabetes in the U. K. population. Diabetes. 2004;53(11): 3002-3006.
124. Barroso I, Luan J, Wheeler E, et al. Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. Diabetes. 2008;57(11): 3161-3165.
125. Bjørkhaug L, Sagen JV, Thorsby P, Søvik O, Molven A, Njølstad PR. Hepatocyte nuclear factor-1 α gene mutations and diabetes in Norway. J Clin Endocrinol Metab. 2003;88(2): 920-931.
126. Nowak N, Hohendorff J, Solecka I, et al. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus. Endocrine. 2015;50(3): 643-649.
127. Brial F, Lussier CR, Belleville K, Sarret P, Boudreau F. Ghrelin inhibition restores glucose homeostasis in hepatocyte nuclear factor-1α (MODY3)-deficient mice. Diabetes. 2015;64(9): 3314-3320.
128. Dezaki K, Kakei M, Yada T. Ghrelin uses Gα i2 and activates voltage-dependent K+ channels to attenuate glucoseinduced Ca2+ signaling and insulin release in islet β -cells: novel signal transduction of ghrelin. Diabetes. 2007;56(9): 2319-2327.
129. Eeckhoute J, Moerman E, Bouckenooghe T, et al. Hepatocyte nuclear factor 4 α isoforms originated from the P1 promoter are expressed in human pancreatic β -cells and exhibit stronger transcriptional potentials than P2 promoter-driven isoforms. Endocrinology. 2003;144(5): 1686-1694.
130. Gupta RK, Vatamaniuk MZ, Lee CS, et al. The MODY1 gene HNF-4α regulates selected genes involved in insulin secretion. J Clin Invest. 2005;115(4): 1006-1015.
131. Sandovici I, Smith NH, Nitert MD, et al. Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. Proc Natl Acad Sci USA. 2011;108(13): 5449-5454.
132. Coffinier C, Thépot D, Babinet C, Yaniv M, Barra J. Essential role for the homeoprotein vHNF1/HNF1β in visceral endoderm differentiation. Development. 1999;126(21): 4785-4794.
133. Barbacci E, Reber M, Ott MO, Breillat C, Huetz F, Cereghini S. Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. Development. 1999;126(21): 4795-4805.
134. Wang L, Coffinier C, Thomas MK, et al. Selective deletion of the Hnf1β (MODY5)gene inβ -cells leads to altered gene expression and defective insulin release. Endocrinology. 2004;145(8): 3941-3949.
135. De Vas MG, Kopp JL, Heliot C, Sander M, Cereghini S, Haumaitre C. Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors. Development. 2015;142(5): 871-882.
136. Poll AV, Pierreux CE, Lokmane L, et al. A vHNF1/TCF2-HNF6 cascade regulates the transcription factor network that controls generation of pancreatic precursor cells. Diabetes. 2006;55(1): 61-69.
137. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β -cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(4): 200-213.
138. Chen YZ, Gao Q, Zhao XZ, et al. Systematic review of TCF2 anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5. Chin Med J. 2010;123(22): 3326-3333.
139. Edghill EL, Stals K, Oram RA, Shepherd MH, Hattersley AT, Ellard S. HNF1B deletions in patients with youngonset diabetes but no known renal disease. Diabet Med. 2013;30(1): 114-117.
140. Haldorsen IS, Vesterhus M, Raeder H, et al. Lack of pancreatic body and tail in HNF1B mutation carriers. Diabet Med. 2008;25(7): 782-787.
141. Winckler W, Weedon MN, Graham RR, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young(MODY)genes for association with type 2 diabetes. Diabetes. 2007;56(3): 685-693.
142. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161(2): 147-152.
143. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7): 1674-1685.
144. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8): 977-983.
145. Barbacci E, Chalkiadaki A, Masdeu C, et al. HNF1β /TCF2 mutations impair transactivation potential through altered co-regulator recruitment. Hum Molec Genet. 2004;13(24): 3139-3149.
146. Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, Cereghini S. Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1β /MODY5 mutations. Hum Molec Genet. 2006;15(15): 2363-2375.
147. Cha JY, Kim H, Kim KS, Hur MW, Ahn Y. Identification of transacting factors responsible for the tissue-specific expression ofhumanglucose transporter type 2 isoform gene. Cooperative role of hepatocyte nuclear factors 1α and 3β. J Biol Chem. 2000;275(24): 18358-18365.
148. Kim EK, Lee JS, Cheong HI, Chung SS, Kwak SH, Park KS. Identification and functional characterization of P159L mutation in HNF1B in a family with maturity-onset diabetes of the young 5 (MODY5). Genomics Inform. 2014;12(4): 240-246.
149. Yamagata K, Nammo T, Moriwaki M, et al. Overexpression of dominant-negative mutant hepatocyte nuclear fctor-1 α in pancreatic β -cells causes abnormal islet architecture with decreased expression of E-cadherin, reducedβ -cell proliferation, and diabetes. Diabetes. 2002;51(1): 114-123.
150. Dessimoz J, Bonnard C, Huelsken J, Grapin-Botton A. Pancreas-specific deletion ofβ -catenin reveals Wnt-dependent and Wnt-independent functions during development. Curr Biol. 2005;15(18): 1677-1683.
151. Papadopoulou S, Edlund H. Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes. 2005;54(10): 2844-2851.
152. Murtaugh LC, Law AC, Dor Y, Melton DA. β -Catenin is essential for pancreatic acinar but not islet development. Development. 2005;132(21): 4663-4674.
153. Oliver-Krasinski JM, Stoffers DA. On the origin of the β cell. Genes Dev. 2008;22(15): 1998-2021.
154. Oliver-Krasinski JM, Kasner MT, Yang J, et al. The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. J Clin Invest. 2009;119(7): 1888-1898.
155. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. β -Cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the β -cell phenotype and maturity onset diabetes. Genes Dev. 1998;12(12): 1763-1768.
156. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 1994;371(6498): 606-609.
157. Gao T, McKenna B, Li C, et al. Pdx1 maintains β cell identity and function by repressing an β cell program. Cell Metab. 2014;19(2): 259-271.
158. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997;15(1): 106-110.
159. Wright NM, Metzger DL, Borowitz SM, Clarke WL. Permanent neonatal diabetes mellitus and pancreatic exocrine insufficiency resulting from congenital pancreatic agenesis. Am J Dis Child. 1993;147(6): 607-609.
160. Schwitzgebel VM, Mamin A, Brun T, et al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab. 2003;88(9): 4398-4406.
161. Nicolino M, Claiborn KC, Senée V, Boland A, Stoffers DA, Julier C. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes. 2010;59(3): 733-740.
162. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet. 1997;17(2): 138-139.
163. Weng J, Macfarlane WM, Lehto M, et al. Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. Diabetologia. 2001;44(2): 249-258.
164. Hani EH, Stoffers DA, Chèvre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in lateonset type 2 diabetes mellitus. J Clin Invest. 1999;104(9): R41-R48.
165. Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest. 1999;104(9): R33-R39.
166. Edghill EL, Khamis A, Weedon MN, et al. Sequencing PDX1 (insulin promoter factor 1) in 1788 UK individuals found 5% had a low frequency coding variant, but these variants are not associated with Type 2 diabetes. Diabet Med. 2011;28(6): 681-684.
167. Steinthorsdottir V, Thorleifsson G, Sulem P, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet. 2014;46(3): 294-298.
168. Sachdeva MM, Claiborn KC, Khoo C, et al. Pdx1 (MODY4) regulates pancreatic β cell susceptibility to ER stress. Proc Natl Acad Sci USA. 2009;106(45): 19090-19095.
169. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(2): 92-103.
170. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4): 537-577.
171. Soleimanpour SA, Ferrari AM, Raum JC, et al. Diabetes susceptibility genes Pdx1 and Clec16a function in a pathway regulating mitophagy in β -cells. Diabetes. 2015;64(10): 3475-3484.
172. Smith SB, Ee HC, Conners JR, German MS. Paired-homeodomain transcription factor PAX4 acts as a transcriptional repressor in early pancreatic development. Molec Cell Biol. 1999;19(12): 8272-8280.
173. Brun T, Gauthier BR. Afocus on the role of Pax4 in mature pancreatic islet β -cell expansion and survival in health and disease. J Mol Endocrinol. 2008;40(2): 37-45.
174. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulinproducing β cells in the mammalian pancreas. Nature. 1997;386(6623): 399-402.
175. Collombat P, Mansouri A, Hecksher-Sorensen J, et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes Dev. 2003;17(20): 2591-2603.
176. Collombat P, Hecksher-Sørensen J, Broccoli V, et al. The simultaneous loss of Arx and Pax4 genes promotes a somatostatin-producing cell fate specification at the expense of the α - and β -cell lineages in the mouse endocrine pancreas. Development. 2005;132(13): 2969-2980.
177. Plengvidhya N, Kooptiwut S, Songtawee N, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007;92(7): 2821-2826.
178. Kooptiwut S, Plengvidhya N, Chukijrungroat T, et al. Defective PAX4 R192H transcriptional repressor activities associated with maturity onset diabetes of the young and early onset-age of type 2 diabetes. J Diabetes Complications. 2012;26(4): 343-347.
179. Jo W, Endo M, Ishizu K, Nakamura A, Tajima T. A novel PAX4 mutation in a Japanese patient with maturity-onset diabetes of the young. Tohoku J Exp Med. 2011;223(2): 113-118.
180. Shimajiri Y, Sanke T, Furuta H, et al. A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes. 2001;50(12): 2864-2869.
181. Ma RC, Hu C, Tam CH, et al. Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4. Diabetologia. 2013;56(6): 1291-1305.
182. Chen M, Hu C, Zhang R, et al. Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. Pharmacogenomics J. 2014;14(5): 488-492.
183. Biason-Lauber A, Boehm B, Lang-Muritano M, et al. Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to β cell regenerative capacity. Diabetologia. 2005;48(5): 900-905.
184. Holm P, Rydlander B, Luthman H, Kockum I. Interaction and association analysis of a type 1 diabetes susceptibility locus on chromosome 5q11-q13 and the 7q32 chromosomal region in Scandinavian families. Diabetes. 2004;53(6): 1584-1591.
185. Hermann R, Mantere J, Lipponen K, et al. Lack of association of PAX4 gene with type 1 diabetes in the Finnish and Hungarian populations. Diabetes. 2005;54(9): 2816-2819.
186. Zhang Y, Xiao X, Liu Y, et al. The association of the PAX4 gene with type 1 diabetes in Han Chinese. Diabetes Res Clin Pract. 2008;81(3): 365-369.
187. Mauvais-Jarvis F, Smith SB, Le May C, et al. PAX4 gene variations predispose to ketosis-prone diabetes. Hum Molec Genet. 2004;13(24): 3151-3159.
188. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008;29(3): 292-302.
189. + ketosis-prone diabetes. Diabetes. 2013;62(3): 912-922.
190. Haaland WC, Scaduto DI, Maldonado MR, et al. A-β - subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. Diabetes Care. 2009;32(5): 873-877.
191. Brun T, Franklin I, St-Onge L, et al. The diabetes-linked transcription factor PAX4 promotes β -cell proliferation and survival in rat and human islets. J Cell Biol. 2004;167(6): 1123-1135.
192. Docena MK, Faiman C, Stanley CM, Pantalone KM. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy. Endocr Pract. 2014;20(2): 107-111.
193. Østoft SH, Bagger JI, Hansen T, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37(7): 1797-1805.
194. Lumb AN, Gallen IW. Treatment of HNF1-α MODYwith the DPP-4 inhibitor sitagliptin(1). Diabet Med. 2009;26(2): 189-190.
195. Katra B, Klupa T, Skupien J, et al. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients-report of two cases. Diabetes Technol Ther. 2010;12(4): 313-316.
196. Lefèbvre PJ, Paquot N, Scheen AJ. Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obes Metab. 2015;17(8): 720-725.
197. Naya FJ, Huang HP, Qiu Y, et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuro D-deficient mice. Genes Dev. 1997;11(18): 2323-2334.
198. Gu C, Stein GH, Pan N, et al. Pancreatic β cells require Neuro D to achieve and maintain functional maturity. Cell Metab. 2010;11(4): 298-310.
199. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODYin Iceland is associated with mutations in HNF-1α and a novel mutation in Neuro D1. Diabetologia. 2001;44(11): 2098-2103.
200. Liu L, Furuta H, Minami A, et al. A novel mutation, Ser159Pro in the Neuro D1/BETA2 gene contributes to the development of diabetes in a Chinese potential MODY family. Mol Cell Biochem. 2007; 303: 115-120.
201. Gonsorcíková L, Prúhová S, Cinek O, et al. Autosomal inheritance of diabetes in two families characterized by obesity and a novel H241Q mutation in NEUROD1. Pediatr Diabetes. 2008; 9: 367-372.
202. Szopa M, Ludwig-Galezowska AH, Radkowski P, et al. A family with the Arg103Pro mutation in the NEUROD1 gene detected by next-generation sequencing-clinical characteristics of mutation carriers. Eur J Med Genet. 2016;59(2): 75-79.
203. Rubio-Cabezas O, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes. 2010;59(9): 2326-2331.
204. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999;23(3): 323-328.
205. Liu L, Jia W, Zheng T, Li M, Lu H, Xiang K. Ala45Thr variation in neuro D1 gene is associated with early-onset type 2 diabetes with or without diabetic pedigree in Chinese. Mol Cell Biochem. 2006; 290: 199-204.
206. Malecki MT, Cyganek K, Klupa T, Sieradzki J. The Ala45Thr polymorphism of BETA2/Neuro D1 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Acta Diabetol. 2003;40(2): 109-111.
207. Han X, Xiao J, Ren Q, Tang Y, Yang W, Ji L. Evaluation of variant A45T in NEUROD1/BETA2 for its association with type 2 diabetes mellitus. Endocrine. 2013;44(1): 99-106.
208. Hansen L, Jensen JN, Urioste S, et al. Neuro D/BETA2 gene variability and diabetes: no associations to late-onset type 2 diabetes but an A45 allele may represent a susceptibility marker for type 1 diabetes among Danes. Danish Study Group of Diabetes in Childhood, and the Danish IDDM Epidemiology and Genetics Group. Diabetes. 2000;49(5): 876-878.
209. Malecki MT, Klupa T, Moczulski DK, Rogus JJ. The Ala45Thr polymorphism of BETA2/Neuro D1 gene and susceptibility to type 1 diabetes mellitus in Caucasians. Exp Clin Endocrinol Diabetes. 2003;111(5): 251-254.
210. Oliveira CS, Hauache OM, Vieira JG, et al. The Ala45Thr polymorphism of NEUROD1 is associated with type 1 diabetes in Brazilian women. Diabetes Metab. 2005;31(6): 599-602.
211. Vella A, Howson JM, Barratt BJ, et al. Lack of association of the Ala(45)Thr polymorphism and other common variants of the Neuro D gene with type 1 diabetes. Diabetes. 2004;53(4): 1158-1161.
212. Naya FJ, Stellrecht CM, Tsai MJ. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev. 1995;9(8): 1009-1019.
213. Zhao L, Guo M, Matsuoka TA, et al. The islet β cell enriched Maf A activator is a key regulator of insulin gene transcription. J Biol Chem. 2005;280(12): 11887-11894.
214. Yang Y, Chang BH, Samson SL, Li MV, Chan L. The Krüppel-like zinc finger protein Glis3 directly and indirectly activates insulin gene transcription. Nucleic Acids Res. 2009;37(8): 2529-2538.
215. Fonseca SG, Fukuma M, Lipson KL, et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic β -cells. J Biol Chem. 2005;280(47): 39609-39615.
216. Rohayem J, Ehlers C, Wiedemann B, et al. Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype. Diabetes Care. 2011;34(7): 1503-1510.
217. Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120(3): 744-755.
218. Zalloua PA, Azar ST, Delépine M, et al. WFS1 mutations are frequent monogenic causes of juvenile-onset diabetes mellitus in Lebanon. Hum Molec Genet. 2008;17(24): 4012-4021.
219. Zmyslowska A, Fendler W, Niwald A, et al. Retinal thinning as a marker of disease progression in patients with Wolfram syndrome. Diabetes Care. 2015;38(3): e36-e37.
220. Rigoli L, Lombardo F, Di Bella C. Wolfram syndrome and WFS1 gene. Clin Genet. 2011;79(2): 103-117.
221. Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet. 2007;81(4): 673-683.
222. Rigoli L, Di Bella C. Wolfram syndrome 1 and Wolfram syndrome 2. Curr Opin Pediatr. 2012;24(4): 512-517.
223. Minton JA, Hattersley AT, Owen K, et al. Association studies of genetic variation in the WFS1 gene and type 2 diabetes in U. K. populations. Diabetes. 2002;51(4): 1287-1290.
224. Sandhu MS, Weedon MN, Fawcett KA, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet. 2007;39(8): 951-953.
225. Cheurfa N, Brenner GM, Reis AF, et al. Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study. Diabetologia. 2011;54(3): 554-562.
226. Fawcett KA, Wheeler E, Morris AP, et al. Detailed investigation of the role ofcommonand low-frequency WFS1variants in type 2 diabetes risk. Diabetes. 2010;59(3): 741-746.
227. Awata T, Inoue K, Kurihara S, et al. Missense variations of the gene responsible for Wolfram syndrome (WFS1/wolframin) in Japanese: possible contribution of the Arg456His mutation to type 1 diabetes as a nonautoimmune genetic basis. Biochem Biophys Res Commun. 2000;268(2): 612-616.
228. Lemaire K, Schuit F. Integrating insulin secretion and ER stress in pancreatic β -cells. Nat Cell Biol. 2012;14(10): 979-981.
229. Lu S, Kanekura K, Hara T, et al. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proc Natl Acad Sci USA. 2014;111(49): E5292-E5301.
230. Huang CJ, Gurlo T, Haataja L, et al. Calcium-activated calpain-2 is a mediator of β cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem. 2010;285(1): 339-348.
231. Hatanaka M, Tanabe K, Yanai A, et al. Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic β -cells. Hum Molec Genet. 2011;20(7): 1274-1284.
232. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5): 557-566.
233. Jonker JW, Suh JM, Atkins AR, et al. A PPARγ -FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 2012;485(7398): 391-394.
234. Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell. 2012;148(3): 556-567.
235. Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci USA. 2012;109(8): 3143-3148.
236. Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature. 2010;466(7305): 451-456.
237. Banks AS, McAllister FE, Camporez JP, et al. An ERK/ Cdk5 axis controls the diabetogenic actions of PPAR γ. Nature. 2015;517(7534): 391-395.
238. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402(6764): 880-883.
239. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPAR γ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR γ 2 missense mutation. Biochem Biophys Res Commun. 1997;241(2): 270-274.
240. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26(1): 76-80.
241. Soriguer F, Morcillo S, Cardona F, et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr. 2006;136(9): 2325-2330.
242. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-γ 2 Pro12Ala polymorphism. Diabetes. 2002;51(8): 2341-2347.
243. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-γ 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010;171(6): 645-655.
244. Raj SM, Howson JM, Walker NM, et al. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009;52(10): 2109-2116.
245. Qu HQ, Grant SF, Bradfield JP, et al. Association analysis of type 2 diabetes loci in type 1 diabetes. Diabetes. 2008;57(7): 1983-1986.
246. Soccio RE, Chen ER, Rajapurkar SR, et al. Genetic variation determines PPARγ function and anti-diabetic drug response in vivo. Cell. 2015;162(1): 33-44.
247. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J. 2014; 13: 17.
248. Bossé Y, Weisnagel SJ, Bouchard C, Després JP, Pérusse L, Vohl MC. Combined effects of PPARγ 2 P12A and PPARα L162V polymorphisms on glucose and insulin homeostasis: the Québec Family Study. J Hum Genet. 2003;48(12): 614-621.
249. Koch M, Rett K, Maerker E, et al. The PPARγ 2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia. 1999;42(6): 758-762.
250. Claussnitzer M, Dankel SN, Klocke B, et al. Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms. Cell. 2014; 156: 343-358.
251. Steiner DF, Tager HS, Chan SJ, Nanjo K, Sanke T, Rubenstein AH. Lessons learned from molecular biology of insulingene mutations. Diabetes Care. 1990;13(6): 600-609.
252. Tager H, Given B, Baldwin D, et al. A structurally abnormal insulin causing human diabetes. Nature. 1979;281(5727): 122-125.
253. Haneda M, Chan SJ, Kwok SC, Rubenstein AH, Steiner DF. Studies on mutant human insulin genes: identification and sequence analysis of a gene encoding [SerB24]insulin. Proc Natl Acad Sci USA. 1983;80(20): 6366-6370.
254. Shoelson S, Fickova M, Haneda M, et al. Identification of a mutant human insulin predicted to contain a serine-forphenylalanine substitution. Proc Natl Acad Sci USA. 1983;80(24): 7390-7394.
255. Nanjo K, Sanke T, Miyano M, et al. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin. J Clin Invest. 1986;77(2): 514-519.
256. Carroll RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, Steiner DF. A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway. Proc Natl Acad Sci USA. 1988;85(23): 8943-8947.
257. Schwartz GP, Burke GT, Katsoyannis PG. A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci USA. 1987;84(18): 6408-6411.
258. Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA. 2007;104(38): 15040-15044.
259. Garin I, Perez de Nanclares G, Gastaldo E, Harries LW, Rubio-Cabezas O, Castano L. Permanent neonatal diabetes caused by creation of an ectopic splice site within the INS gene. PLoS One. 2012;7(1): e29205.
260. Carmody D, Park SY, Ye H, et al. Continued lessons from the INS gene: an intronic mutation causing diabetes through a novel mechanism. J Med Genet. 2015;52(9): 612-616.
261. Dusatkova L, Dusatkova P, Vosahlo J, et al. Frameshift mutations in the insulin gene leading to prolonged molecule of insulin in two families with maturity-onset diabetes of the young. Eur J Med Genet. 2015;58(4): 230-234.
262. Bonfanti R, Colombo C, Nocerino V, et al. Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies. Diabetes Care. 2009;32(1): 123-125.
263. Oda N, Nakai A, Fujiwara K, et al. Polymorphisms of the insulin gene among Japanese subjects. Metabolism. 2001;50(6): 631-634.
264. Flannick J, Beer NL, Bick AG, et al. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet. 2013;45(11): 1380-1385.
265. Park SY, Ye H, Steiner DF, Bell GI. Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted. Biochem Biophys Res Commun. 2010;391(3): 1449-1454.
266. Sunyaev S, Ramensky V, Bork P. Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet. 2000;16(5): 198-200.
267. Støy J, Steiner DF, Park SY, Ye H, Philipson LH, Bell GI. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord. 2010;11(3): 205-215.
268. Molven A, Ringdal M, Nordbø AM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008;57(4): 1131-1135.
269. Wang J, Takeuchi T, Tanaka S, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic β -cell dysfunction in the Mody mouse. J Clin Invest. 1999;103(1): 27-37.
270. Liu M, Hodish I, Rhodes CJ, Arvan P. Proinsulin maturation, misfolding, and proteotoxicity. Proc Natl Acad Sci USA. 2007;104(40): 15841-15846.
271. Ahamed A, Unnikrishnan AG, Pendsey SS, et al. Permanent neonatal diabetes mellitus due to a C96Y heterozygous mutation in the insulin gene. A case report. JOP. 2008;9(6): 715-718.
272. Garin I, Edghill EL, Akerman I, et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc Natl Acad Sci USA. 2010;107(7): 3105-3110.
273. Bakay M, Pandey R, Hakonarson H. Genes involved in type 1 diabetes: an update. Genes. 2013;4(3): 499-521.
274. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INSVNTR alleles at the IDDM2 locus. Nat Genet. 1997;15(3): 289-292.
275. Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol. 2008;20(1): 111-118.
276. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Ann Rev Genet. 1996; 30: 343-370.
277. Meigs JB, Dupuis J, Herbert AG, Liu C, Wilson PW, Cupples LA. The insulin gene variable number tandem repeat and risk of type 2 diabetes in a population-based sample of families and unrelated men and women. J Clin Endocrinol Metab. 2005;90(2): 1137-1143.
278. Hansen SK, Gjesing AP, Rasmussen SK, et al. Large-scale studies of the Hph I insulin gene variable-number-of-tandem-repeats polymorphism in relation to type 2 diabetes mellitus and insulin release. Diabetologia. 2004;47(6): 1079-1087.
279. Huxtable SJ, Saker PJ, Haddad L, et al. Analysis of parentoffspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes. 2000;49(1): 126-130.
280. Lindsay RS, Hanson RL, Wiedrich C, Knowler WC, Bennett PH, Baier LJ. The insulin gene variable number tandem repeat class I/III polymorphism is in linkage disequilibrium with birth weight but not type 2 diabetes in the Pima population. Diabetes. 2003;52(1): 187-193.
281. Brookes KJ. The VNTR in complex disorders: the forgotten polymorphisms? A functional way forward? Genomics. 2013;101(5): 273-281.
282. Saxena R, Elbers CC, Guo Y, et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012;90(3): 410-425.
283. Liu M, Hodish I, Haataja L, et al. Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth. Trends Endocrinol Metab. 2010;21(11): 652-659.
284. Guo H, Xiong Y, Witkowski P, et al. Inefficient translocation of preproinsulin contributes to pancreatic β cell failure and late-onset diabetes. J Biol Chem. 2014;289(23): 16290-16302.
285. Fernández Á F, López-Otín C. The functional and pathodoi: logic relevance of autophagy proteases. J Clin Invest. 2015;125(1): 33-41.
286. Bachar-Wikstrom E, Wikstrom JD, Ariav Y, et al. Stimulation of autophagy improves endoplasmic reticulum stressinduced diabetes. Diabetes. 2013;62(4): 1227-1237.
287. Liu M, Haataja L, Wright J, et al. Mutant INS-gene induced diabetes of youth: proinsulin cysteine residues impose dominant-negative inhibition on wild-type proinsulin transport. PLoS One. 2010;5(10): e13333.
288. Hay CW, Docherty K. Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes. 2006;55(12): 3201-3213.
289. Kang HS, Kim YS, ZeRuth G, et al. Transcription factor Glis3, a novel critical player in the regulation of pancreatic β -cell development and insulin gene expression. Mol Cell Biol. 2009;29(24): 6366-6379.
290. Kim YS, Nakanishi G, Lewandoski M, Jetten AM. GLIS3, a novel member of the GLIS subfamily of Krüppel-like zinc finger proteins with repressor and activation functions. Nucleic Acids Res. 2003;31(19): 5513-5525.
291. Senée V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet. 2006;38(6): 682-687.
292. Dimitri P, Warner JT, Minton JA, et al. Novel GLIS3 mutations demonstrate an extended multisystem phenotype. Eur J Endocrinol. 2011;164(3): 437-443.
293. Dimitri P, Habeb AM, Garbuz F, et al. Expanding the clinical spectrum associated with GLIS3 mutations. J Clin Endocrinol Metab. 2015;100(10): E1362-E1369.
294. Cao B, Gong C, Wu D, et al. Genetic analysis and follow-up of 25 neonatal diabetes mellitus patients in China. J Diabetes Res. 2016; 2016: 6314368.
295. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6): 703-707.
296. Kiani AK, John P, Bhatti A, et al. Association of 32 type 1 diabetes risk loci in Pakistani patients. Diabetes Res Clin Pract. 2015;108(1): 137-142.
297. Winkler C, Krumsiek J, Buettner F, et al. Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. Diabetologia. 2014;57(12): 2521-2529.
298. Boesgaard TW, Grarup N, Jørgensen T, et al. Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated β cell function in middle-aged Danish people. Diabetologia. 2010;53(8): 1647-1655.
299. Liu C, Li H, Qi L, et al. Variants in GLIS3 and CRY2 are associated with type 2 diabetes and impaired fasting glucose in Chinese Hans. PLoS One. 2011;6(6): e21464.
300. Hu C, Zhang R, Wang C, et al. Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One. 2010;5(11): e15542.
301. Rees SD, Hydrie MZ, O'Hare JP, et al. Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLoS One. 2011;6(9): e24710.
302. Cho YS, Chen CH, Hu C, et al. Meta-analysis of genomewide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet. 2012;44(1): 67-72.
303. Barker A, Sharp SJ, Timpson NJ, et al. Association of genetic loci with glucose levels in childhood and adolescence: a meta-analysis of over 6, 000 children. Diabetes. 2011;60(6): 1805-1812.
304. Sakai K, Imamura M, Tanaka Y, et al. Replication study for the association of 9 East Asian GWAS-derived loci with susceptibility to type 2 diabetes in a Japanese population. PLoS One. 2013;8(9): e76317.
305. ZeRuth GT, Takeda Y, Jetten AM. The Krüppel-like protein Gli-similar 3 (Glis3) functions as a key regulator of insulin transcription. Mol Endocrinol. 2013;27(10): 1692-1705.
306. Yang Y, Chang BH, Chan L. Sustained expression of the transcription factor GLIS3 is required for normal β cell function in adults. EMBO Mol Med. 2013;5(1): 92-104.
307. Watanabe N, Hiramatsu K, Miyamoto R, et al. A murine model of neonatal diabetes mellitus in Glis3-deficient mice. FEBS Lett. 2009;583(12): 2108-2113.
308. Yang Y, Chang BH, Yechoor V, et al. The Krüppel-like zinc finger protein GLIS3 transactivates neurogenin 3 for proper fetal pancreatic islet differentiation in mice. Diabetologia. 2011;54(10): 2595-2605.
309. Georgia S, Bhushan A. β -Cell replication is the primary mechanism for maintaining postnatal β cell mass. J Clin Invest. 2004;114(7): 963-968.
310. Kushner JA, Ciemerych MA, Sicinska E, et al. Cyclins D2 and D1are essential for postnatal pancreaticβ -cell growth. Mol Cell Biol. 2005;25(9): 3752-3762.
311. Georgia S, Hinault C, Kawamori D, et al. Cyclin D2 is essential for the compensatoryβ -cell hyperplastic response to insulin resistance in rodents. Diabetes. 2010;59(4): 987-996.
312. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9): 981-990.
313. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β -cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4): 219-226.
314. Cnop M, Ladrière L, Igoillo-Esteve M, Moura RF, Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic β -cell dysfunction. Diabetes Obes Metab. 2010; 12(suppl 2): 76-82.
315. Nogueira TC, Paula FM, Villate O, et al. GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic β cell apoptosis via regulation of a splice variant of the BH3-only protein Bim. PLoS Genet. 2013;9(5): e1003532.
316. Thomsen SK, Gloyn AL. The pancreatic β cell: recent insights from human genetics. Trends Endocrinol Metab. 2014;25(8): 425-434.
317. Gaulton KJ, Nammo T, Pasquali L, et al. A map of open chromatin in human pancreatic islets. Nat Genet. 2010;42(3): 255-259.
318. Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46(2): 136-143.